TFF Pharmaceuticals Announces Completion of Enrollment and Preliminary Data from its Phase 1 Clinical Trial of Tacrolimus Inhalation Powder

~ Inhaled Tacrolimus Powder Achieves Systemic Therapeutic Drug Levels ~ Anticipate Additional Safety Data in 3Q 2021 ~ Initiation of Lung Transplant Study Expected in 2H 2021

Daniel Carlson

July 13, 2021

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

4 COMMENTS

carpenitodm July 16, 2021 at 4:57 pm

You need to login to view this content.

Reply
pfalker July 15, 2021 at 12:23 pm

You need to login to view this content.

Reply
- Daniel Carlson July 16, 2021 at 11:00 am
  
  You need to login to view this content.
  
  Reply
  - Peter Falker July 16, 2021 at 11:24 am
    
    You need to login to view this content.
    
    Reply

LEAVE A REPLY Cancel reply

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.